Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

Author： Becerra Carlos   Salazar Ramon   Garcia-Carbonero Rocio   Thomas Anne   Vázquez-Mazón Federico   Cassidy James   Maughan Tim   Castillo Manuel   Iveson Tim   Yin Donghua   Green Stephanie   Bergsland Emily  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.73, Iss.4, 2014-04, pp. : 695-702

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

By Molife L.   Rudman Sarah   Alam Salma   Tan Daniel   Kristeleit Hartmut   Middleton Gary   Propper David   Bent Liz   Stopfer Peter   Uttenreuther-Fischer Martina   Wallenstein Gudrun   de Bono Johann   Spicer James  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1213-1222

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer

By Meadows Sherry   Mulkerin Daniel   Berlin Jordan   Bailey Howard   Kolesar Jill   Warren Deb   Thomas James  

International Journal of Gastrointestinal Cancer, Vol. 32, Iss. 2-3, 2002-12 ,pp. : 125-128

Humana Press, Inc

Access to resources Recommend Favorite

Phase II Trial of Gemcitabine plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Ovarian Cancer Patients

By Nagourney R.A.   Brewer C.A.   Radecki S.   Kidder W.A.   Sommers B.L.   Evans S.S.   Minor D.R.   DiSaia P.J.  

Gynecologic Oncology, Vol. 88, Iss. 1, 2003-01 ,pp. : 35-39

Academic Press

Access to resources Recommend Favorite

Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial

By van Poznak C.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 3, 2001-04 ,pp. : 239-248

Springer Publishing Company

Access to resources Recommend Favorite

Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

By Markman M.   Kennedy A.   Sutton G.   Hurteau J.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 2, 1998-08 ,pp. : 272-274

Elsevier

Access to resources Recommend Favorite